Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanamivir - Vaxart/GlaxoSmithKline

Drug Profile

Zanamivir - Vaxart/GlaxoSmithKline

Alternative Names: 4-guanidino Neu5Ac2en; Dectova; GG 167; GR 121167; GR-121167X; Relenza

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biota Holdings; Monash University
  • Developer GSK
  • Class Antivirals; Guanidines; Pyrans; Sialic acids
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 26 Jan 2023 Phase-II clinical trials in Influenza virus infections (In infants, In neonates) in United Kingdom, Spain (IV) (NCT04494412)
  • 23 Oct 2020 Phase-II clinical trials in Influenza virus infections (In neonates, In infants) in Poland, Netherlands (IV) (NCT04494412)
  • 31 Jul 2020 GlaxoSmithKline plans a phase II pharmacokinetics trial for Influenza virus infections (In infants, In neonates) (IV, infusion) in October 2020 (NCT04494412)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top